Dihexa can be structurally classified as a synthetic peptide analogue containing amino acid-derived residues linked through multiple amide bonds
No foul play is suspected
Locally, Indias largest pharma firm Sun Pharmaceutical Industries is developing its own weight-loss formulation, while Cipla and Reddys Laboratories are working on generic drugs
By identifying your genetic predispositions, PlexusDx helps you make informed decisions about whether to adjust your current compound or try a new onewithout guessing or trial-and-error cycling
Prime Therapeutics' leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years News provided by Prime Therapeutics LLC Jun 25, 2025, 10:00 ET Findings also show improved persistence with high-potency, obesity-approved GLP-1 products EAGAN, Minn., June 25, 2025 /PRNewswire/ -- Only 8% of individuals (or 1 in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to do so at three years, according to the latest real-world research from pharmacy solutions partner Prime Therapeutics LLC (Prime)
